Mamitaro Ohtsuki

9.5k total citations · 5 hit papers
186 papers, 6.8k citations indexed

About

Mamitaro Ohtsuki is a scholar working on Immunology, Dermatology and Pathology and Forensic Medicine. According to data from OpenAlex, Mamitaro Ohtsuki has authored 186 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 116 papers in Immunology, 84 papers in Dermatology and 35 papers in Pathology and Forensic Medicine. Recurrent topics in Mamitaro Ohtsuki's work include Psoriasis: Treatment and Pathogenesis (88 papers), Dermatology and Skin Diseases (55 papers) and Autoimmune Bullous Skin Diseases (27 papers). Mamitaro Ohtsuki is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (88 papers), Dermatology and Skin Diseases (55 papers) and Autoimmune Bullous Skin Diseases (27 papers). Mamitaro Ohtsuki collaborates with scholars based in Japan, United States and Germany. Mamitaro Ohtsuki's co-authors include Mayumi Komine, Jitlada Meephansan, Koji Kamiya, Hidemi Nakagawa, Megumi Kishimoto, Junichi Sugai, Andrew Blauvelt, Kim Papp, Miroslav Blumenberg and Md Razib Hossain and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Mamitaro Ohtsuki

169 papers receiving 6.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Role of Matrix Metalloproteinases in Photoaging and Photocarcinogenesis

2016 822 citations Jitlada Meephansan, Mayumi Komine et al. International Journal of Molecular Sciences profile →
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

2016 650 citations Andrew Blauvelt, Kim Papp et al. profile →
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

2018 452 citations Bruce Strober, Mark Lebwohl et al. profile →
Risk Factors for the Development of Psoriasis

2019 396 citations Koji Kamiya, Megumi Kishimoto et al. International Journal of Molecular Sciences profile →
Inflammatory Molecules Associated with Ultraviolet Radiation-Mediated Skin Aging

2021 232 citations Md Razib Hossain, Koji Kamiya et al. International Journal of Molecular Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mamitaro Ohtsuki Japan	38	3.8k	3.4k	906	900	821	186	6.8k
Paola Di Meglio United Kingdom	33	4.8k 1.3×	2.3k 0.7×	1.0k 1.2×	1.5k 1.6×	534 0.7×	61	7.1k
Knud Kragballe Denmark	53	5.2k 1.4×	3.6k 1.1×	1.2k 1.3×	2.2k 2.4×	866 1.1×	256	9.2k
Kamran Ghoreschi Germany	44	4.4k 1.2×	1.7k 0.5×	811 0.9×	1.7k 1.9×	1.3k 1.6×	143	8.2k
Yayoi Tada Japan	35	2.3k 0.6×	1.9k 0.6×	703 0.8×	589 0.7×	602 0.7×	175	4.1k
Errol P. Prens Netherlands	51	3.6k 1.0×	8.0k 2.4×	887 1.0×	1.1k 1.2×	532 0.6×	219	11.2k
Erwin Schöpf Germany	44	2.1k 0.6×	3.6k 1.0×	1.2k 1.3×	690 0.8×	1.4k 1.8×	196	8.1k
Gerald D. Weinstein United States	46	3.2k 0.9×	3.3k 1.0×	349 0.4×	1.2k 1.4×	908 1.1×	132	7.4k
J.‐P. Ortonne France	30	2.0k 0.5×	1.5k 0.4×	314 0.3×	498 0.6×	556 0.7×	69	3.4k
R.D.R. Camp United Kingdom	37	2.2k 0.6×	2.1k 0.6×	992 1.1×	691 0.8×	609 0.7×	98	5.2k
Leon Kircik United States	28	1.4k 0.4×	2.8k 0.8×	362 0.4×	313 0.3×	418 0.5×	356	4.2k

Countries citing papers authored by Mamitaro Ohtsuki

Since Specialization

Citations

This map shows the geographic impact of Mamitaro Ohtsuki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mamitaro Ohtsuki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mamitaro Ohtsuki more than expected).

Fields of papers citing papers by Mamitaro Ohtsuki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mamitaro Ohtsuki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mamitaro Ohtsuki. The network helps show where Mamitaro Ohtsuki may publish in the future.

Co-authorship network of co-authors of Mamitaro Ohtsuki

This figure shows the co-authorship network connecting the top 25 collaborators of Mamitaro Ohtsuki. A scholar is included among the top collaborators of Mamitaro Ohtsuki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mamitaro Ohtsuki. Mamitaro Ohtsuki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thaçi, Diamant, Mamitaro Ohtsuki, Julia‐Tatjana Maul, et al.. (2025). Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months. Dermatology and Therapy. 15(2). 381–394. 5 indexed citations

Torii, Hideshi, Akimichi Morita, Chie Yamamoto, et al.. (2025). Safety and effectiveness of ixekizumab in Japanese patients with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis: Post‐marketing surveillance. The Journal of Dermatology. 52(5). 787–801. 1 indexed citations

Okubo, Yukari, Akimichi Morita, Shinichi Imafuku, et al.. (2025). Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: In‐Depth Analysis of Efficacy and Safety in the Phase 3 POETYK PSO ‐4 Trial. The Journal of Dermatology. 52(6). 953–966.

Armstrong, April W., Mark Lebwohl, Richard B. Warren, et al.. (2024). Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years. JAMA Dermatology. 161(1). 56–56. 11 indexed citations

Hossain, Md Razib, et al.. (2024). Overexpression of the β-Subunit of Acid Ceramidase in the Epidermis of Mice Provokes Atopic Dermatitis-like Skin Symptoms. International Journal of Molecular Sciences. 25(16). 8737–8737.

Ohtsuki, Mamitaro, Yukari Okubo, Hidehisa Saeki, et al.. (2024). Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post‐marketing surveillance study. The Journal of Dermatology. 51(7). 950–963. 3 indexed citations

Armstrong, April W., Mark Lebwohl, Richard B. Warren, et al.. (2024). Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal of Cutaneous Medicine. 8(4). s406–s406. 2 indexed citations

Saeki, Hidehisa, Masashi Akiyama, Masatoshi Abe, et al.. (2023). English version of Japanese guidance for biologics in treating atopic dermatitis. The Journal of Dermatology. 50(10). e311–e322. 6 indexed citations

Takeuchi, Tsutomu, Kiyohiro Nishikawa, Akimichi Morita, et al.. (2023). Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies. Drug Safety. 46(10). 991–1005. 3 indexed citations

10.

Kamiya, Koji, et al.. (2023). A case of Kyrle's disease successfully treated with topical benzoyl peroxide. SHILAP Revista de lepidopterología. 6(5). 192–193. 1 indexed citations

11.

Kishimoto, Megumi, Mayumi Komine, Koji Kamiya, et al.. (2023). Four‐year drug survival of apremilast in patients with psoriasis. The Journal of Dermatology. 50(7). 960–963. 3 indexed citations

12.

Imafuku, Shinichi, Hidemi Nakagawa, Atsuyuki Igarashi, et al.. (2021). Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1). The Journal of Dermatology. 48(6). 844–852. 6 indexed citations

13.

Fujita, Hideki, Mamitaro Ohtsuki, Akimichi Morita, et al.. (2020). Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real‐world evidence in Japan. The Journal of Dermatology. 48(2). 175–183. 24 indexed citations

14.

Ohtsuki, Mamitaro, Hideki Fujita, Masao Watanabe, et al.. (2019). Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial. The Journal of Dermatology. 46(8). 686–694. 79 indexed citations

15.

Meephansan, Jitlada, et al.. (2017). Methotrexate, but not narrowband ultraviolet B radiation, suppresses interleukin‐33 mRNA levels in psoriatic plaques and protein levels in serum of patients with psoriasis. The Journal of Dermatology. 45(3). 322–325. 11 indexed citations

16.

Papp, Kim, C. Leonardi, Andrew Blauvelt, et al.. (2017). Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). British Journal of Dermatology. 178(3). 674–681. 77 indexed citations

17.

Papp, Kim, Robert Bissonnette, Mamitaro Ohtsuki, et al.. (2016). 059 Ixekizumab shows no association with MACE in patients with moderate-to-severe psoriasis: an integrated safety analysis of clinical trials. Journal of Investigative Dermatology. 136(9). S170–S170. 2 indexed citations

18.

Nakajima, Rina, Mayumi Komine, Yukiko Miyamoto, et al.. (2015). Sarcomatoid carcinoma arising in the congenital pigmented nevus after treatment with carbon dioxide snow freezing method. The Journal of Dermatology. 42(11). 1083–1086.

19.

Nakajima, Hiroaki, et al.. (2010). Astaxanthin attenuates the UVA-induced up-regulation of matrix-metalloproteinase-1 and skin fibroblast elastase in human dermal fibroblasts. Journal of Dermatological Science. 58(2). 136–142. 119 indexed citations

20.

Nakagawa, Hidemi, Setsuya Aiba, Akihiko Asahina, et al.. (2004). A Consensus Conference Report on Psoriasis Therapy with Cyclosporine MEPC. 114(6). 1093–1105. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact